SEC Comment Letter 0000000000-25-000966 to Foghorn Therapeutics Inc. (FHTX) (CIK 0001822462) (FHTX)
Foghorn Therapeutics Inc. (FHTX) (CIK 0001822462)
Date: Jan. 29, 2025 · CIK: 0001822462 · Accession: 0000000000-25-000966
AI Filing Summary & Sentiment
File numbers found in text: 333-284476
Letter
January 29, 2025 Adrian Gottschalk Chief Executive Officer Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 Re:Foghorn Therapeutics Inc. Registration Statement on Form S-3 Filed January 24, 2025 File No. 333-284476 Dear Adrian Gottschalk: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Rachel Phillips, Esq.
Show Raw Text
January 29, 2025
Adrian Gottschalk
Chief Executive Officer
Foghorn Therapeutics Inc.
500 Technology Square, Suite 700
Cambridge, MA 02139
Re:Foghorn Therapeutics Inc.
Registration Statement on Form S-3
Filed January 24, 2025
File No. 333-284476
Dear Adrian Gottschalk:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Rachel Phillips, Esq.